The blog
Clinical trial results, TGA regulatory progress and research updates on retatrutide and the wider peptide space — explained for Australians.
14 September 2026 · tesamorelin · peptides · pharmacokinetics · regulation · australia
Tesamorelin's approved dose fell from 2 mg to 1.28 mg with no change to the molecule. The sub-4% bioavailability story, the bioequivalence data, and the Australian status.
Read more →11 September 2026 · tesamorelin · peptides · cognition · ghrh · australia
Tesamorelin research on cognition: a 2012 trial showed executive-function gains, a 2025 HIV trial missed. What that means, plus tesamorelin Australia rules.
Read more →9 September 2026 · tesamorelin · peptides · research · australia · ghrh
A 2026 meta-analysis of five RCTs found tesamorelin cut visceral and liver fat but not BMI. What the evidence shows, plus tesamorelin's Australian status.
Read more →Stay informed
Retatrutide is not yet available to the public. But when it is, you will want to be first to know. Sign up to receive:
Get the free guide + updates
Enter your details once on our free access guide page — instant download, plus we'll email you the moment there's real news.